Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury

[Image: see text] Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients. Herein we describe the presence of tolvaptan- and tolvaptan-metabolite-responsive T cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Andrew, Hammond, Sean, Jaruthamsophon, Kanoot, Roth, Sharin, Mosedale, Merrie, Naisbitt, Dean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672698/
https://www.ncbi.nlm.nih.gov/pubmed/33085478
http://dx.doi.org/10.1021/acs.chemrestox.0c00328
_version_ 1783611186407800832
author Gibson, Andrew
Hammond, Sean
Jaruthamsophon, Kanoot
Roth, Sharin
Mosedale, Merrie
Naisbitt, Dean J.
author_facet Gibson, Andrew
Hammond, Sean
Jaruthamsophon, Kanoot
Roth, Sharin
Mosedale, Merrie
Naisbitt, Dean J.
author_sort Gibson, Andrew
collection PubMed
description [Image: see text] Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients. Herein we describe the presence of tolvaptan- and tolvaptan-metabolite-responsive T cell clones within the peripheral circulation of patients with liver injury. Drug treatment of the clones resulted in a proliferative response and secretion of IFN-γ, IL-13, and the cytolytic molecule granzyme B. Future work should explore pathways of tolvaptan driven T cell activation and the role of T cells in the disease pathogenesis.
format Online
Article
Text
id pubmed-7672698
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-76726982020-11-19 Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury Gibson, Andrew Hammond, Sean Jaruthamsophon, Kanoot Roth, Sharin Mosedale, Merrie Naisbitt, Dean J. Chem Res Toxicol [Image: see text] Tolvaptan is an effective drug for the treatment of autosomal dominant polycystic kidney disease, but its use is associated with a significant risk of liver injury in a small number of patients. Herein we describe the presence of tolvaptan- and tolvaptan-metabolite-responsive T cell clones within the peripheral circulation of patients with liver injury. Drug treatment of the clones resulted in a proliferative response and secretion of IFN-γ, IL-13, and the cytolytic molecule granzyme B. Future work should explore pathways of tolvaptan driven T cell activation and the role of T cells in the disease pathogenesis. American Chemical Society 2020-10-21 2020-11-16 /pmc/articles/PMC7672698/ /pubmed/33085478 http://dx.doi.org/10.1021/acs.chemrestox.0c00328 Text en © 2020 American Chemical Society This is an open access article published under a Creative Commons Attribution (CC-BY) License (http://pubs.acs.org/page/policy/authorchoice_ccby_termsofuse.html) , which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
spellingShingle Gibson, Andrew
Hammond, Sean
Jaruthamsophon, Kanoot
Roth, Sharin
Mosedale, Merrie
Naisbitt, Dean J.
Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
title Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
title_full Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
title_fullStr Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
title_full_unstemmed Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
title_short Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
title_sort tolvaptan- and tolvaptan-metabolite-responsive t cells in patients with drug-induced liver injury
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672698/
https://www.ncbi.nlm.nih.gov/pubmed/33085478
http://dx.doi.org/10.1021/acs.chemrestox.0c00328
work_keys_str_mv AT gibsonandrew tolvaptanandtolvaptanmetaboliteresponsivetcellsinpatientswithdruginducedliverinjury
AT hammondsean tolvaptanandtolvaptanmetaboliteresponsivetcellsinpatientswithdruginducedliverinjury
AT jaruthamsophonkanoot tolvaptanandtolvaptanmetaboliteresponsivetcellsinpatientswithdruginducedliverinjury
AT rothsharin tolvaptanandtolvaptanmetaboliteresponsivetcellsinpatientswithdruginducedliverinjury
AT mosedalemerrie tolvaptanandtolvaptanmetaboliteresponsivetcellsinpatientswithdruginducedliverinjury
AT naisbittdeanj tolvaptanandtolvaptanmetaboliteresponsivetcellsinpatientswithdruginducedliverinjury

Ejemplares similares